研究单位：[1]Fudan University[2]Fudan University[3]LinkDoc Technology (Beijing) Co. Ltd.[4]Huazhong University of Science and Technology[5]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China[6]The First Affiliated Hospital of USTC, Anhui Provincial Hospital,Hefei,Anhui,China[7]Cancer Hospital Chinese Academy of Medical Science,Beijing,Beijing,China[8]Fujian Cancer Hospital,Fuzhou,Fujian,China[9]Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,Guangdong,China[10]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China[11]The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital,Shijia Zhuang,Hebei,China[12]The First Affiliates Hospital of Ha''erbin University,Ha''erbin,Heilongjiang,China[13]Henan Provincial People''s Hospital,Zhengzhou,Henan,China[14]Hubei Cancer Hospital,Wuhan,Hubei,China[15]Renmin Hospital of Wuhan University,Wuhan,Hubei,China[16]Tongji Medical College of HUST,Wuhan,Hubei,China[17]Union Hospital Tongji Medical College Huazhong Univeristy of Science and Technology,Wuhan,Hubei,China[18]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China[19]Jiangsu Province Hospital of Chinese Medicine,Nanjing,Jiangsu,China[20]Jiangsu Provincial Hospital,Nanjing,Jiangsu,China[21]Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School,Nanjing,Jiangsu,China[22]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[23]Northern Jiangsu People''s Hospital,Yangzhou,Jiangsu,China[24]The Second Hospital of Jilin University,Chang chun,Jilin,China[25]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China[26]Qilu Hospital of Shandong University,Jinan,Shandong,China[27]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[28]LongHua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai,Shanghai,China[29]The Second Affiliated Hospital of Xi''an Jiaotong University (Xibei Hospital),Xi''an,Shanxi,China[30]The First Affiliatied Hospital Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[31]The Second Affiliated Hospital Zhejiang Univerisity of Medicine,Hangzhou,Zhejiang,China[32]Huamei Hospital, University of Chinese Academy of Sciences,Ningbo,Zhejiang,China[33]The First School of Medicine, School of Information and Engineering,the First Affiliated Hospital of WMU,Wenzhou,Zhejiang,China
This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.
